4Q Revenues: $320.5 million (+41%)
4Q Earnings: $81.0 million (+68%)
FY Revenues: $1.1 billion (+45%)
FY Earnings: $254.8 million (+45%)
Comments: Soliris sales were $320.5 million in the quarter, up 41%, and $1.1 billion for the year, up 45% driven by steady additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) globally, and an increasing number of new patients with atypical Hemolytic Uremic Syndrome (aHUS).